[64Cu]FBP8 PET for Cardiac Amyloidosis

This trial tests a new imaging technique using a special PET/MRI scan with [64Cu]FBP8 to detect blood clots in the heart. It focuses on individuals with cardiac amyloidosis who also experience irregular heartbeats, such as atrial fibrillation or atrial flutter. The trial seeks participants who have recently undergone a heart scan (TEE) and are managing these heart conditions. The researchers aim to demonstrate that this new method can identify clots more than 90% of the time when present. Participants must be able to lie still in a scanner and should not have certain implants or severe medical conditions. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking diagnostic advancement.

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that if your anticoagulation medication is changed after a TEE, there is a 72-hour window before PET/MR imaging. It's best to discuss your specific medications with the trial team.

In a previous study, researchers found that the investigational substance [64Cu]FBP8 was well-tolerated by participants. The study included eight healthy volunteers and some patients with blood clot-related conditions. It showed that this substance leaves the blood quickly and is mostly removed through the kidneys. Researchers checked vital signs, such as heart rate and blood pressure, before and after scans and did not report any serious side effects.

Researchers are excited about [64Cu]FBP8 because it offers a novel approach to diagnosing cardiac amyloidosis. Unlike traditional imaging methods, [64Cu]FBP8 uses a special copper-based tracer in combination with PET/MR technology to provide more precise and detailed images of the heart. This could potentially lead to earlier and more accurate diagnosis, which is crucial for managing cardiac amyloidosis effectively. By targeting specific amyloid deposits, this method may improve the ability to monitor disease progression and response to treatment, offering a significant advancement over current diagnostic techniques.

Research has shown that [64Cu]FBP8 is a promising tool for detecting blood clots inside the heart. Studies have demonstrated that this PET scan method can identify clots in over 90% of cases confirmed by other imaging tests, highlighting its effectiveness. Additionally, tests have confirmed the probe's safety, showing low radiation levels and quick elimination from the body. In this trial, participants with cardiac amyloidosis and atrial fibrillation/atrial flutter will undergo [64Cu]FBP8 PET/MR to potentially enhance the diagnosis of heart conditions related to amyloidosis.²³⁶⁷⁸